Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating Yttrium-90 ibritumomab tiuxetan in combination with rituximab for post-transplant lymphoproliferative disorder and related B-cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Post-transplant Lymphoproliferative Disorder
• Waldenström Macroglobulinemia

Drugs mentioned

• Rituxan (rituximab)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma | Phase 1, Phase 2 | Status: COMPLETED